Sarda Proteins

  • Market Cap: Small Cap
  • Industry: Edible Oil
  • ISIN: INE995U01011
  • NSEID:
  • BSEID: 519242
INR
78.60
0.00 (0.00%)
BSENSE

Dec 04

BSE+NSE Vol: 14

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

14 (-99.04%) Volume

Shareholding (Sep 2024)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

0.00%

Is Sarda Proteins overvalued or undervalued?

09-Jun-2025

As of January 6, 2025, Sarda Proteins Ltd. is considered overvalued with a "risky" rating due to high financial ratios, including a PE Ratio of 22.60 and a Price to Book Value of 9.54, despite a strong 1-year return of 62.51%.

As of 6 January 2025, Sarda Proteins Ltd. has moved from a grade of "does not qualify" to "risky," indicating a shift in its valuation outlook. The company appears to be overvalued based on its current financial ratios. The PE Ratio stands at 22.60, while the Price to Book Value is significantly high at 9.54, and the EV to Sales ratio is 21.29, all suggesting that the stock price may not be justified by its earnings or asset value.<BR><BR>In comparison to its peers, Sarda Proteins' PE ratio is higher than the industry average, which raises concerns about its valuation. Notably, its EV to EBITDA is -22.57, indicating negative earnings before interest, taxes, depreciation, and amortization, which is a significant red flag. While the company has outperformed the Sensex with a 1-year return of 62.51% compared to the Sensex's 7.57%, this performance may not be sustainable given the current valuation metrics. Overall, Sarda Proteins appears to be overvalued in the current market environment.

Read More

What is the technical trend for Sarda Proteins?

09-Jun-2025

As of May 20, 2025, Sarda Proteins shows a mildly bullish trend with mixed signals from indicators like the MACD, Bollinger Bands, and RSI, suggesting caution despite the current price being at a 52-week high of 137.45.

As of 20 May 2025, the technical trend for Sarda Proteins has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly RSI shows bearish momentum. Daily moving averages remain bullish, supporting the current price of 137.45, which is at a 52-week high. The KST is mildly bearish on a weekly basis but bullish monthly, and Dow Theory reflects a mildly bullish outlook in both time frames. Overall, the strength of the bullish trend is tempered by mixed signals in the RSI and KST, suggesting caution despite the positive indicators.

Read More

When is the next results date for Sarda Proteins?

27-Nov-2025

The next results date for Sarda Proteins is 29 November 2025.

The next results date for Sarda Proteins is scheduled for 29 November 2025.

Read More

How has been the historical performance of Sarda Proteins?

01-Dec-2025

Sarda Proteins has shown significant sales growth, with net sales rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, but faced challenges with increased expenditures, resulting in marginal operating profit and a decrease in profit after tax and EPS. Overall, while sales and total assets have grown, profitability remains a concern.

Answer:<BR>The historical performance of Sarda Proteins shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Sarda Proteins experienced a notable increase in net sales, rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, following a trend of varying sales figures over the previous years. The total operating income also reflected this growth, reaching 24.19 Cr in Mar'25 compared to 1.30 Cr in the prior year. However, the company faced challenges with total expenditure, which increased to 24.17 Cr in Mar'25 from 1.44 Cr in Mar'24. This resulted in a marginal operating profit of 0.02 Cr in Mar'25, a slight improvement from the losses recorded in earlier years. The profit before tax remained stable at 0.02 Cr for both Mar'25 and Mar'24, while profit after tax showed a decrease to 0.01 Cr in Mar'25 from 0.02 Cr in Mar'24. The earnings per share (EPS) also reflected this trend, decreasing to 0.06 in Mar'25 from 0.12 in Mar'24. On the balance sheet, total assets increased to 2.53 Cr in Mar'25 from 2.30 Cr in Mar'24, driven by a rise in short-term loans and advances. Overall, while Sarda Proteins has shown growth in sales and total assets, profitability metrics indicate ongoing challenges.

Read More

Should I buy, sell or hold Sarda Proteins?

02-Dec-2025

Why is Sarda Proteins falling/rising?

04-Dec-2025

As of 04-Dec, Sarda Proteins Ltd's stock price is at 78.60, reflecting a decline of 2.0%. The stock has shown significant underperformance, with weak long-term fundamentals and a return of -27.12% over the past year.

As of 04-Dec, Sarda Proteins Ltd's stock price is falling, currently at 78.60, which reflects a decrease of 1.6 (-2.0%). The stock has underperformed significantly in the short term, with a 1-week decline of 2.24%, compared to a modest drop of 0.53% in the Sensex. Additionally, the stock opened with a loss of 2% today and reached an intraday low of Rs 78.6, indicating a lack of upward momentum.<BR><BR>The company's long-term fundamentals are weak, evidenced by a -6.89% CAGR growth in operating profits over the last five years and a poor EBIT to Interest ratio of -0.01, suggesting difficulties in servicing its debt. Furthermore, the stock has generated a return of -27.12% over the past year, with profits declining by 11%. This underperformance is compounded by the fact that the stock has also lagged behind the BSE500 index over various time frames, including the last three years and one year.<BR><BR>While there was a notable increase in delivery volume on December 1, rising by 2622.4% against the 5-day average, this does not seem to have translated into positive price movement. The stock's performance today has been characterized by erratic trading, with no significant price range and trading lower than several moving averages. Overall, these factors contribute to the stock's downward trend.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with a -6.89% CAGR growth in Operating Profits over the last 5 years

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.01
  • The company has been able to generate a Return on Equity (avg) of 3.34% signifying low profitability per unit of shareholders funds
2

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Edible Oil

stock-summary
Market cap

INR 14 Cr (Small Cap)

stock-summary
P/E

339.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

1.75%

stock-summary
Price to Book

6.07

Revenue and Profits:
Net Sales:
4 Cr
(Quarterly Results - Sep 2025)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
-27.12%
0%
-27.12%
2 Years
87.37%
0%
87.37%
3 Years
-50.05%
0%
-50.05%
4 Years
138.54%
0%
138.54%
5 Years
727.37%
0%
727.37%

Sarda Proteins for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Announcements stock-summary

Results - Financial Results Sept 2025

29-Nov-2025 | Source : BSE

Results - Financial Results 2025

Board Meeting Outcome for Outcome Of Board Meeting

29-Nov-2025 | Source : BSE

Results - Outcome of Board Meeting

Board Meeting Intimation for Results

26-Nov-2025 | Source : BSE

Sarda Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/11/2025 inter alia to consider and approve the unaudited financial results for the quarter and half year ended on 30th September 2025.

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
23.26%
EBIT Growth (5y)
-6.89%
EBIT to Interest (avg)
-0.01
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
3.34
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-0.62%
ROE (avg)
3.34%
Valuation key factors
Factor
Value
P/E Ratio
339
Industry P/E
0
Price to Book Value
5.95
EV to EBIT
-13.60
EV to EBITDA
-13.60
EV to Capital Employed
5.89
EV to Sales
0.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.66%
ROE (Latest)
1.75%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Ritika Vegetable Oil Private Limited (0.0%)

Highest Public shareholder

Uday R Shah (huf) (4.26%)

Individual Investors Holdings

89.2%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -60.73% vs 0.00% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 181.63% vs -345.45% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.30",
          "val2": "10.95",
          "chgp": "-60.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.30",
          "val2": "-0.50",
          "chgp": "160.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.40",
          "val2": "-0.49",
          "chgp": "181.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "6.98%",
          "val2": "-4.57%",
          "chgp": "11.55%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 10,800.00% vs -41.67% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -400.00% vs 400.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.26",
          "val2": "0.14",
          "chgp": "10,800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.19",
          "val2": "0.02",
          "chgp": "-1,050.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.09",
          "val2": "0.03",
          "chgp": "-400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.25%",
          "val2": "14.29%",
          "chgp": "-15.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Mar 2025 is -88.71% vs -75.49% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Mar 2025 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.14",
          "val2": "1.24",
          "chgp": "-88.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.08",
          "val2": "-0.13",
          "chgp": "38.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.08",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-57.14%",
          "val2": "-10.48%",
          "chgp": "-46.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 1,760.77% vs -77.59% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -50.00% vs 166.67% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.19",
          "val2": "1.30",
          "chgp": "1,760.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.02",
          "val2": "-0.14",
          "chgp": "114.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.01",
          "val2": "0.02",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.08%",
          "val2": "-10.77%",
          "chgp": "10.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQstock-summary
Sep'25
Jun'25
Change(%)
Net Sales
4.30
10.95
-60.73%
Operating Profit (PBDIT) excl Other Income
0.30
-0.50
160.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
0.40
-0.49
181.63%
Operating Profit Margin (Excl OI)
6.98%
-4.57%
11.55%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is -60.73% vs 0.00% in Jun 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is 181.63% vs -345.45% in Jun 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
15.26
0.14
10,800.00%
Operating Profit (PBDIT) excl Other Income
-0.19
0.02
-1,050.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.09
0.03
-400.00%
Operating Profit Margin (Excl OI)
-1.25%
14.29%
-15.54%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 10,800.00% vs -41.67% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -400.00% vs 400.00% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Dec'23
Change(%)
Net Sales
0.14
1.24
-88.71%
Operating Profit (PBDIT) excl Other Income
-0.08
-0.13
38.46%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.08
0.00
Operating Profit Margin (Excl OI)
-57.14%
-10.48%
-46.66%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Mar 2025 is -88.71% vs -75.49% in Dec 2023

Standalone Net Profit

YoY Growth in nine months ended Mar 2025 is 0.00% vs 0.00% in Dec 2023

Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
24.19
1.30
1,760.77%
Operating Profit (PBDIT) excl Other Income
0.02
-0.14
114.29%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
0.01
0.02
-50.00%
Operating Profit Margin (Excl OI)
0.08%
-10.77%
10.85%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 1,760.77% vs -77.59% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -50.00% vs 166.67% in Mar 2024

stock-summaryCompany CV
About Sarda Proteins Ltd stock-summary
stock-summary
Sarda Proteins Ltd
Small Cap
Edible Oil
Sarda Proteins Ltd was incorporated in December 03, 1991. The company is mainly engaged in the distribution of refined oil, mustard oil and trading of Agro products like wheat, sesame seed, mustard seed, Guar seed and other edible products backed up with strong distribution network.The company had an opening paid up capital as on 1st April 2015 Rs. 2,43,48,500. The company issued a final notice during the year 2015-16 to holders of 16,96,500 partly paid shares of Rs.
Company Coordinates stock-summary
Company Details
B-536-537, Matsya Industrial Area Alwar Rajasthan : 301030
stock-summary
Tel: 91-144-2881392
stock-summary
sardaproteins@yahoo.com
Registrar Details
Link Intime India Pvt Ltd., Narang Tower 44, Community Centre, Naraina Industrial Area , Phase - 1, New Delhi